European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma
Journal Paper/Review - Aug 31, 2010
Engelhardt Monika, Straka Christian, Johnsen Hans E, Waage Anders, Boegsted Martin, Lokhorst Henk, Hájek Roman, Morgan Gareth, Boccadoro Mario, Ludwig Heinz, Cavo Michele, Polliack Aaron, Sonneveld Pieter, Einsele Hermann, Kropff Martin, Sezer Orhan, Udi Josefina, Kleber Martina, Spencer Andrew, Rocci Alberto, Knop Stefan, Bruno Benedetto, Bringhen Sara, Pérez-Simón José A, Zweegman Sonja, Driessen Christoph, Patriarca Francesca, Gramatzki Martin, Terpos Evangelos, Palumbo Antonio
Over the past two decades, not only treatment options, but also the diagnosis, staging, and risk assessment of multiple myeloma (MM), have undergone significant development, partially due to a deeper understanding of MM pathogenesis. Conventional cytogenetics and fluorescence in situ hybridization are routinely assessed in MM, and when combined with ISS stage may attain an even better predictive potential. In order to achieve even more effective and individualized therapies, one crucial goal is the identification of genes and gene combinations that predict for response or resistance to chemotherapy. High-dose chemotherapy with autologous stem cell transplant (SCT) still remains the standard therapy for younger patients, with novel agents now being included in both pre-transplant regimens and post-transplant consolidation/maintenance approaches. Similarly, novel agents are also being incorporated into allogeneic SCT for selected patients. In the treatment of elderly patients with MM, novel agents have been successfully incorporated into less intensive regimens, including melphalan/prednisone, low-dose dexamethasone, and cyclophosphamide/dexamethasone. While second-generation proteasome inhibitors are currently being intensively investigated, the subcutaneous administration of bortezomib, being equivalent to the established i.v. route, is now entering clinical practice. Supportive care remains a crucial aspect in the management of MM. The European Myeloma Network Trialist Group aims to address these contemporary aspects in MM.